CARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve human health, today ...

Active Motif, a leading provider of epigenetics and multiomic solutions to mechanistic, translational, and clinical researchers, today announced an exclusive global commercial distribution agreement ...

Enhanced Genomics’ 3D multi-omics platform harnessed to rapidly identify multiple novel therapeutic targets that were undetectable using conventional genomic approaches Breakthrough demonstrates the ...

Enhanced Genomics ('Enhanced'), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced it has ...

Enhanc3D Genomics (‘Enhanced’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug ...

The partnership enables Fox Chase to become the first NCI-designated Comprehensive Cancer Center to implement clinical testing utilizing Arima's 3D-genomics technology in multiple tumor types as part ...

The genome is more than a linear code; it is a dynamic structure whose three-dimensional folding dictates how genes are regulated. Traditional sequencing technologies capture base-level variation but ...

Agreement expands Active Motif's research genomics portfolio while supporting Arima's strategic focus on its clinical diagnostics platform CARLSBAD, Calif., July 6, 2026 /PRNewswire/ -- Active Motif, ...